US20040166067A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
US20040166067A1
US20040166067A1 US10/753,628 US75362804A US2004166067A1 US 20040166067 A1 US20040166067 A1 US 20040166067A1 US 75362804 A US75362804 A US 75362804A US 2004166067 A1 US2004166067 A1 US 2004166067A1
Authority
US
United States
Prior art keywords
fentanyl
composition according
chitosan
pharmaceutically acceptable
pectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/753,628
Other languages
English (en)
Inventor
Peter Watts
Jonathan Castile
William Lafferty
Alan Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Assertio Therapeutics Inc
Original Assignee
West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9950919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040166067(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Assigned to WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED reassignment WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASTILE, JONATHAN DAVID, SMITH, ALAN, WATTS, PETER JAMES, LAFFERTY, WILLIAM COLUMBUS IAN
Publication of US20040166067A1 publication Critical patent/US20040166067A1/en
Assigned to ARCHIMEDES DEVELOPMENT LIMITED reassignment ARCHIMEDES DEVELOPMENT LIMITED CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED
Priority to US12/047,388 priority Critical patent/US8216604B2/en
Priority to US13/541,314 priority patent/US8889176B2/en
Priority to US13/541,325 priority patent/US9078814B2/en
Assigned to DEERFIELD PRIVATE DESIGN FUND III, L.P. reassignment DEERFIELD PRIVATE DESIGN FUND III, L.P. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DEPOMED, INC.
Priority to US14/747,289 priority patent/US9814705B2/en
Assigned to ASSERTIO THERAPEUTICS, INC. reassignment ASSERTIO THERAPEUTICS, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: DEPOMED, INC.
Assigned to ASSERTIO THERAPEUTICS, INC. reassignment ASSERTIO THERAPEUTICS, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBERS 09402976, 10196590, 11562002,11562173,12047388,13078575,13541314,13541325, 14747289 PREVIOUSLY RECORDED ON REEL 047322 FRAME 0843. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Assignors: DEPOMED, INC.
Assigned to ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.) reassignment ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.) RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS COLLATERAL AGENT
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to pharmaceutical compositions for the intranasal administration of fentanyl.
  • the nasal route of drug delivery can afford rapid onset of action and convenience to patients and/or care giver.
  • this route can provide rapid absorption of drugs into the blood circulation.
  • absorption of almost the whole dose can be achieved and the pharmacokinetics can be similar to intravenous administration.
  • Such rapid and effective drug delivery can be useful in the treatment of crisis situations such as pain, including breakthrough pain, headache and migraine (Nasal Systemic Drug Delivery, Chien et al. (eds), Dekker, New York, 1987).
  • Fentanyl (N-(1-phenethyl-4-piperidyl)propionanilide) is a potent opioid analgesic and may be used in the treatment of severe acute and chronic pain.
  • fentanyl intranasal administration of fentanyl appears to have been achieved by dropping or spraying a commercially available injection formulation into the nose (SUBLIMAZE®, from Janssen).
  • the commercially available injection formulation of fentanyl contains 0.05 mg of fentanyl, in the form of the citrate salt, in 1 ml of sodium chloride solution and necessitates the intranasal administration of a large volume of liquid in order to provide a therapeutically effective dose of drug.
  • Fentanyl is also currently available in a transdermal patch and a transmucosal lozenge.
  • the transdermal patch for example DUROGESIC® from Janssen
  • the transmucosal lozenge (ACTIQ®, Cephalon Inc) is used in the treatment of breakthrough pain and is available in a number of dose strengths ranging from 0.2 to 1.6 mg.
  • the absorption of fentanyl from the transmucosal formulation is relatively slow. Times to achieve the peak plasma concentration (T max ) of from 20 to 480 minutes have been reported (pp. 405-409, Physician's Desk Reference, 54th edition, Medical Economics Company, Montvale, N.J., 2000).
  • the present invention provides a composition suitable for the intranasal administration of fentanyl that overcomes one or more of the problems described above.
  • AUC area under the plasma concentration vs. time curve
  • simple aqueous solution fentanyl and an ingredient to make the solution isotonic, such as mannitol, dextrose or sodium chloride, dissolved in water.
  • a simple aqueous solution may optionally contain a preservative, such as benzalkonium chloride.
  • An example of such a simple aqueous solution comprises 1.57 mg/ml fentanyl citrate, 48 mg/ml mannitol and 0.15 mg/ml benzalkonium chloride in water.
  • the present invention provides a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal, which comprises an aqueous solution of
  • composition comprises a pectin it is substantially free of agents that cause the pectin to gel, such as divalent metal ions, especially calcium ions.
  • the additive may be a pectin, a poloxamer, a chitosan (or a salt or derivative thereof) or it may be a mix of two or more of these additives.
  • the compositions of the present invention provide a lowered peak plasma concentration of fentanyl (C max ) and optionally an extended plasma-concentration time profile.
  • the peak plasma concentration (C max ) achieved using a composition of the present invention is from 10 to 80%, preferably from 20 to 75% and more preferably from 30 to 70% of that achieved using a simple aqueous solution administered intranasally at an identical fentanyl dose.
  • the C max produced by a composition of this invention following administration of an identical dose of fentanyl is in the range 100-800 ⁇ g/ml, preferably 200-750 ⁇ g/ml and more preferably 300-700 ⁇ g/ml.
  • the time to achieve the peak plasma concentration (T max ) by nasal administration of a composition of the present invention is preferably from 5 to 60 minutes, more preferably from 5 to 45 minutes and most preferably from 5 to 30 minutes.
  • Fentanyl is preferably used in the form of a pharmaceutically acceptable salt. Most preferably fentanyl citrate is used.
  • the concentration of fentanyl or a salt thereof in the compositions of the invention is preferably in the range of from 0.05 to 30 mg/ml, more preferably from 0.1 to 20 mg/ml and most preferably from 0.2 to 16 mg/ml (expressed as fentanyl base).
  • pharmaceutically acceptable is readily understood in the art and can be considered to include materials that may be used in commercially available pharmaceutical or food products and/or have GRAS (generally regarded as safe) status and/or are listed in a pharmacopoeia such as the United States Pharmacopoeia or the European Pharmacopoeia.
  • the present invention provides a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof, comprising an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pectin and which provides a peak plasma concentration (C max ) of fentanyl of from 10 to 80% of that achieved using a simple aqueous solution administered intranasally at an identical fentanyl dose.
  • C max peak plasma concentration
  • Pectins are polysaccharide substances present in the cell walls of all plant tissues. Commercially they are generally obtained from the dilute acid extract of the inner portion of the rind of citrus fruits or from apple pomace. Pectins are heterogeneous materials, comprising partially methoxylated polygalacturonic acids.
  • the proportion of galacturonic acid moieties in the methyl ester form represents the degree of esterification (DE).
  • DE degree of esterification
  • the term “DE” is well understood by those skilled in the art and may be represented as the percentage of the total number of carboxyl groups that are esterified, i.e., if four out of five acid groups is esterified this represents a degree of esterification of 80%, or as the methoxyl content of the pectin. The respective theoretical maximum for each is 100% and 16% respectively.
  • “DE” as used herein refers to the total percentage of carboxyl groups that are esterified.
  • the degree of esterification (DE) of pectins found naturally can vary considerably (from 60 to 90%).
  • Pectins can be categorized into those having a low degree of esterification (low methoxylation) or a high degree of esterification (high methoxylation).
  • a “low DE” or “LM” pectin has a degree of esterification below 50% whereas a “high DE” or “HM” pectin has a degree of esterification of 50% or above.
  • the gelling properties of aqueous pectin solutions can be controlled by the concentration of pectin, the type of pectin, especially the degree of esterification of the galacturonic acid units, and the presence of added salts.
  • Preferably low DE pectins are used in the compositions of the present invention. More preferably pectins having a degree of esterification of less than 35%, for example from 5 to 35%, preferably from 7 to 30%, such as from about 10 to about 25%, for example from 15 to 25% are used in the present invention.
  • Low DE pectins are usually prepared by the de-esterification of extracted pectins, normally on a bench scale, by way of an enzymatic process, or, on an industrial scale, by treatment with acid or ammonia in an alcoholic heterogeneous medium. Treatment with ammonia creates so-called low DE amidated pectins.
  • low DE pectin includes both amidated and non-amidated low DE pectins.
  • Low DE pectins may be purchased commercially.
  • An example of a low DE pectin which may be used in the present invention is SLENDID® 100, supplied by CP Kelco (Lille Skensved, Denmark) which has a degree of esterification of about 15 to 25%.
  • solutions containing a pectin are substantially free of agents that cause the pectin to gel, such as divalent metal ions, especially calcium ions.
  • divalent metal ions especially calcium ions.
  • substantially free of divalent metal ions it is meant greater than 97%, preferably greater than 99%, more preferably greater than 99.9% and especially greater than 99.99% free of divalent metal ions.
  • a composition of the invention contains a pectin
  • the concentration of pectin is preferably in the range of from 1 to 40 mg/ml, more preferably from 2 to 30 mg/ml and most preferably from 5 to 25 mg/ml.
  • a preferred pectin containing composition of the invention comprises 0.2 to 16 mg/ml of fentanyl (expressed as fentanyl base) and 5 to 25 mg/ml of a pectin having a DE value of from 7 to 30% and has a pH of from 3.4 to 5.0 and an osmolality of from 0.25 to 0.35 osmol/kg.
  • the present invention provides a composition comprising fentanyl or a pharmaceutically acceptable salt thereof and a poloxamer and chitosan or a salt or derivative thereof.
  • Poloxamers are block copolymers of ethylene oxide and propylene oxide. They have the general formula HO(C 2 H 4 O) a (C 3 H 6 O) b (C 2 H 4 O) a H wherein a is typically from 2 to 130 and b is typically from 15 to 67. Poloxamers have a number of pharmaceutical applications such as viscosity modifiers, solubilising agents or emulsifiers.
  • compositions of the present invention may be used in the compositions of the present invention as thickening agents and in order to control and modify the absorption of fentanyl into the systemic circulation such that a peak plasma concentration (C max ) of fentanyl of from 10 to 80% of that achieved using a simple aqueous solution administered intranasally at an identical fentanyl dose is achieved.
  • C max peak plasma concentration
  • poloxamer Several different types are available commercially, from suppliers such as BASF, and vary with respect to molecular weight and the proportions of ethylene oxide “a” units and propylene oxide “b” units. Poloxamers suitable for use in the present invention typically have a molecular weight of from 2,500 to 18,000, for example from 7,000 to 15,000 Da.
  • poloxamers suitable for use in the present invention include poloxamer 188, which structurally contains 80 “a” units and 27 “b” units, and has a molecular weight in the range 7680 to 9510 and poloxamer 407 which structurally contains 101 “a” units and 56 “b” units, and has a molecular weight in the range 9840 to 14600 (Handbook of Pharmaceutical Excipients, editor A. H. Kippe, 3 rd edition, Pharmaceutical Press, London, United Kingdom, 2000).
  • the poloxamer is poloxamer 188.
  • the poloxamer is preferably present at a concentration in the range of from 50 to 200 mg/ml, more preferably from 65 to 160 mg/ml and most preferably from 80 to 120 mg/ml.
  • compositions of the invention that comprise a poloxamer also comprise chitosan or a salt or derivative thereof.
  • Chitosans are cationic polymers that have mucoadhesive properties.
  • the mucoadhesion is thought to result from an interaction between the positively charged chitosan molecule and the negatively charged sialic acid groups on mucin (Soane et al. Int. J. Pharm., 178, 55-65, 1999).
  • chitosan all derivatives of chitin, or poly-N-acetyl-D-glucosamine, including all polyglucosamines and oligomers of glucosamine materials of different molecular weights, in which the greater proportion of the N-acetyl groups have been removed through hydrolysis (deacetylation).
  • the chitosan is produced from chitin by deacetylation to a degree of greater than 40%, preferably between 50 and 98%, more preferably between 70% and 90%.
  • the chitosan, chitosan derivative, or salt used in the present invention preferably has a molecular weight of 4,000 Da or more, preferably from 10,000 to 1,000,000 Da, more preferably from 15,000 to 750,000 Da and most preferably from 50,000 to 300,000 Da.
  • Salts of chitosan are suitable for use in the present invention.
  • Suitable salts include, but are not limited to, the nitrate, phosphate, glutamate, lactate, citrate, hydrochloride and acetate salts.
  • Preferred salts are chitosan glutamate and chitosan hydrochloride.
  • Chitosan derivatives are also suitable for use in the present invention.
  • Suitable chitosan derivatives include, but are not limited to, ester, ether or other derivatives formed by bonding acyl and/or alkyl groups with the hydroxyl groups, but not the amino groups of chitosan. Examples are O-alkyl ethers of chitosan and O-acyl esters of chitosan. Modified chitosans, such as those conjugated to polyethylene glycol may be used in the present invention.
  • Low and medium viscosity chitosans suitable for use in the present invention may be obtained from various sources, including NovaMatrix, Drammen, Norway; Seigagaku America Inc., Maryland, United States of America; Meron (India) Pvt, Ltd., India; Vanson Ltd, Virginia, United States of America; and AMS Biotechnology Ltd., United Kingdom. Suitable derivatives include those that are disclosed in Roberts, Chitin Chemistry, MacMillan Press Ltd., London (1992).
  • chitosan compounds include the “PROTOSANTM” types available from NovaMatrix, Drammen, Norway.
  • the chitosan, or salt or derivative thereof is water-soluble.
  • An aqueous solution of chitosan may be prepared by dissolving chitosan base or a derivative of chitosan base in a pharmaceutically acceptable mineral or organic acid such as hydrochloric, lactic, citric or glutamic acid or by dissolving a chitosan salt or a salt of a chitosan derivative in water.
  • a pharmaceutically acceptable mineral or organic acid such as hydrochloric, lactic, citric or glutamic acid
  • compositions of the present invention comprise chitosan, a chitosan salt or a chitosan derivative
  • concentration of chitosan is preferably from 0.1 to 20 mg/ml, more preferably from 0.5 to 15 mg/ml and most preferably from 1 to 10 mg/ml (expressed as chitosan base).
  • a preferred poloxamer and chitosan containing composition of the invention comprises 0.2 to 16 mg/ml of fentanyl (expressed as fentanyl base), 80 to 120 mg/ml of a poloxamer having a molecular weight of from 7,000 to 15,000 Da and 1 to 10 mg/ml (expressed as chitosan base) of a chitosan having a molecular weight of from 50,000 to 300,000 Da or a salt or derivative thereof and has a pH of from 3.0 to 5.0 and an osmolality of from 0.4 to 0.7 osmol/kg.
  • the pH of the compositions of the invention may be regulated.
  • buffered aqueous solutions may be used.
  • the pH of the compositions of the present invention may be adjusted using any pharmaceutically acceptable acidifying or alkalizing agent that is compatible with the other components of the compositions.
  • suitable pharmaceutically acceptable acidifying agents include, but are not limited to, hydrochloric acid, acetic acid, citric acid, methane sulphonic acid, lactic acid, tartaric acid, fumaric acid and malic acid.
  • pharmaceutically acceptable alkalizing agents include, but are not limited to, sodium hydroxide, potassium hydroxide, meglumine, tromethamine, sodium bicarbonate, monoethanolamine, diethanolamine and triethanolamine.
  • the acidifying agent or alkalizing agent preferably should not contain an alkali metal or alkaline earth metal ion, for example it should not be sodium hydroxide, potassium hydroxide or sodium bicarbonate.
  • the pH of the compositions of the invention is generally preferably from 3 to 6.
  • the pH is more preferably from 3.2 to 5.5 and most preferably from 3.4 to 5.0.
  • the pH is more preferably from 3.0 to 5.5 and most preferably from 3.0 to 5.0.
  • compositions of the invention are well tolerated by the patient when administered to the nose (for example when sprayed into the nasal cavity), it is advantageous that they have an osmolality close to that of plasma.
  • the osmolality is generally preferably from 0.1 to 1.0 osmol/kg.
  • the osmolality is more preferably from 0.2 to 0.8 osmol/kg, still more preferably from 0.2 to 0.4 osmol/kg and most preferably from 0.25 to 0.35 osmol/kg.
  • the osmolality is more preferably from 0.2 to 0.9 osmol/kg, still more preferably from 0.3 to 0.8 osmol/kg and most preferably from 0.4 to 0.7 osmol/kg.
  • the osmolality of the compositions of the invention may be adjusted to the desired value by adding any appropriate agent.
  • Salts of metal ions in particular sodium chloride, are commonly used to adjust the osmolality of pharmaceutical preparations.
  • metal ions in particular sodium chloride
  • metal ions for example sodium in the form of sodium chloride
  • compositions containing fentanyl and chitosan results in the formation of a precipitate.
  • the use of metal ion containing agents should preferably be avoided.
  • gel formation in pectin-containing fentanyl compositions and precipitate formation in chitosan-containing fentanyl compositions can be avoided by using a non-metal ion containing compound such as a polyhydric alcohol, for example mannitol or sorbitol, or a sugar, for example dextrose, sucrose or trehalose, to adjust the osmolality.
  • a non-metal ion containing compound such as a polyhydric alcohol, for example mannitol or sorbitol, or a sugar, for example dextrose, sucrose or trehalose.
  • Especially preferred agents to adjust osmolality are mannitol and dextrose at a concentration of up to 50 mg/ml.
  • compositions of the invention may also contain other ingredients such as antioxidants (for example sodium metabisulphite), chelating agents (such as edetic acid or one of its salts), preservatives (such as benzalkonium chloride, sorbic acid or one of its salts, phenylethyl alcohol and/or propyl hydroxybenzoate), sweeteners (such as saccharin or aspartame), flavorings (such as peppermint) or other agents generally used in pharmaceutical liquid preparations and well known to those skilled in the art.
  • antioxidants for example sodium metabisulphite
  • chelating agents such as edetic acid or one of its salts
  • preservatives such as benzalkonium chloride, sorbic acid or one of its salts, phenylethyl alcohol and/or propyl hydroxybenzoate
  • sweeteners such as saccharin or aspartame
  • flavorings such as peppermint
  • compositions of the invention contain a preservative or are sterile.
  • compositions of the invention are non-pyrogenic.
  • composition of the invention can be administered to the nasal cavity in any suitable form, for example in the form of drops or sprays.
  • Methods suitable for administering a composition to the nasal cavity will be well known by the person of ordinary skill in the art. Any suitable method may be used.
  • the preferred method of administration is the use of a spray device.
  • Spray devices can be single (unit) dose or multiple dose systems, for example comprising a bottle, pump and actuator, and are available from various commercial sources including Pfeiffer, Valois, Bespak and Becton-Dickinson.
  • Electrostatic spray devices such as described in U.S. Pat. No. 5,655,517, are also suitable for the intranasal administration of the compositions of the present invention.
  • the typical volume of liquid that is dispensed in a single spray actuation is in the range of from 0.01 to 0.15 ml.
  • a typical dosing regimen for a nasal spray product would be in the range of one spray into a single nostril to two sprays into each nostril.
  • the preferred dose of fentanyl or one of its salts is from 0.01 to 5.0 mg (10 to 5000 ⁇ g), more preferably from 0.015 to 4.0 mg (15 to 4000 ⁇ g) and most preferably from 0.02 to 3.0 mg (20 to 3000 ⁇ g).
  • the present invention also provides a spray device loaded with a composition as defined above.
  • the present invention also provides a process for preparing a composition as described above. This process comprises mixing the components of the composition in water. Purified water such as water for injections may be used.
  • compositions of this invention can be used for the treatment, management or prevention of both acute and chronic pain, in animals including humans.
  • the compositions of the invention can be used to treat, manage or prevent pain a wide variety of pain conditions such as those associated with injury and accident trauma, terminal illness, especially breakthrough pain, and following surgery.
  • the present invention also provides the use of a pharmaceutically acceptable additive selected from
  • a medicament for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal such as a human in need thereof which medicament is adapted to provide a peak plasma concentration of fentanyl (C max ) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose.
  • C max peak plasma concentration of fentanyl
  • the present invention provides the use of a pharmaceutically acceptable additive selected from
  • a medicament for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal such as a human in need thereof suitable for the treatment, prevention or management of acute or chronic pain which medicament is adapted to provide a peak plasma concentration of fentanyl (C max ) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose.
  • FIG. 1 shows mean plasma concentration profiles of fentanyl following the administration of a fentanyl solution comprising chitosan and a fentanyl solution that did not contain chitosan to sheep obtained in Example 7.
  • FIG. 2 shows plasma concentration of fentanyl profiles for three intranasal and one transmucosal formulation obtained in Example 8.
  • pectin STYLE 100, CP Kelco, Denmark
  • pectin solution 1 ml of phenylethyl alcohol (R. C. Treat, United Kingdom) and 40 mg of propyl hydroxybenzoate (Nipa Laboratories, United Kingdom) were added to the pectin solution as preservatives.
  • 314 mg of fentanyl citrate (MacFarlan Smith, Edinburgh, United Kingdom) and 8.3 g of mannitol (Sigma, Poole, United Kingdom) were dissolved in the pectin solution, the solution transferred to a 200 ml volumetric flask and made up to volume with water.
  • the pH of the solution was 4.2 and the osmolality was 0.33 osmol/kg.
  • pectin 4 g was dissolved with stirring in 180 ml of water. 1 ml of phenylethyl alcohol and 40 mg of propyl hydroxybenzoate were added to the pectin solution. 314 mg of fentanyl citrate and 8.3 g of mannitol were dissolved in the pectin solution, the solution was transferred to a 200 ml volumetric flask and made up to volume with water.
  • a 15 mg/ml benzalkonium chloride solution was prepared by weighing 300 mg of 50% benzalkonium chloride aqueous solution (Albright & Wilson, United Kingdom) into a 10 ml volumetric flask, dispersing it in approximately 8 ml of water, then making the solution up to 10 ml with water.
  • the pH of the solution was 3.3 and the osmolality was 0.56 osmol/kg.
  • the pH of the solution was 3.8 and the osmolality was 0.30 osmol/kg.
  • fentanyl citrate 78.5 mg was dissolved in 40 ml of water.
  • 0.5 ml of 15 mg/ml benzalkonium chloride solution and 2.4 g mannitol were added to the fentanyl solution which was stirred until all of the ingredients had dissolved.
  • the solution was transferred to a 50 ml volumetric flask and made up to volume with water.
  • chitosan glutamate 250 mg was dissolved in 40 ml of water.
  • 0.5 ml of 15 mg/ml benzalkonium chloride solution, 78.5 mg fentanyl citrate and 2.4 g mannitol were added to the chitosan solution which was stirred until all of the ingredients had dissolved.
  • the solution was transferred to a 50 ml volumetric flask and made up to volume with water.
  • the solutions prepared in Examples 5 and 6 were administered intranasally to sheep. A group of eight animals, each weighing approximately 60 kg, was used. The doses were administered to a randomized crossover design and each animal received 0.3 ml of each test solution (equivalent to 0.3 mg fentanyl base) intranasally. Nasal doses were administered via a spray device with the dose volume being divided equally between both nostrils.
  • Plasma samples were collected and plasma separated. Plasma samples were assayed by a LC-MS-MS method for fentanyl content.
  • the study was a randomized four-way complete cross-over trial in a group of 18 healthy adult volunteers. Intranasal doses were administered using Pfeiffer Unitdose devices. Each subject received a single spray into one nostril to provide a fentanyl dose of 0.1 mg.
  • the ACTIQ® dose was provided as a lozenge containing 200 ⁇ g (0.2 mg) of fentanyl. The lozenge was administered by dissolving in the mouth over a period of approximately 15 minutes. Plasma samples were collected from the subjects and analyzed for fentanyl content using a LC-MS-MS assay. Pharmacokinetic parameters were calculated from the plasma data.
  • the pharmacokinetic performance of the chitosan solution in the human volunteer study can be considered to be representative of a simple aqueous solution of fentanyl.
  • the intranasal formulations containing pectin and a mixture of poloxamer and chitosan were able to reduce the C max to values of 52% and 68% respectively relative to the nasal chitosan solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
US10/753,628 2003-01-10 2004-01-08 Pharmaceutical compositions Abandoned US20040166067A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/047,388 US8216604B2 (en) 2003-01-10 2008-03-13 Method of managing or treating pain
US13/541,314 US8889176B2 (en) 2003-01-10 2012-07-03 Method of managing or treating pain
US13/541,325 US9078814B2 (en) 2003-01-10 2012-07-03 Intranasal spray device containing pharmaceutical composition
US14/747,289 US9814705B2 (en) 2003-01-10 2015-06-23 Intranasal spray device containing pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0300531.1A GB0300531D0 (en) 2003-01-10 2003-01-10 Pharmaceutical compositions
GB0300531.1 2003-01-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/047,388 Division US8216604B2 (en) 2003-01-10 2008-03-13 Method of managing or treating pain

Publications (1)

Publication Number Publication Date
US20040166067A1 true US20040166067A1 (en) 2004-08-26

Family

ID=9950919

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/753,628 Abandoned US20040166067A1 (en) 2003-01-10 2004-01-08 Pharmaceutical compositions
US12/047,388 Expired - Fee Related US8216604B2 (en) 2003-01-10 2008-03-13 Method of managing or treating pain
US13/541,325 Expired - Fee Related US9078814B2 (en) 2003-01-10 2012-07-03 Intranasal spray device containing pharmaceutical composition
US13/541,314 Expired - Fee Related US8889176B2 (en) 2003-01-10 2012-07-03 Method of managing or treating pain
US14/747,289 Expired - Fee Related US9814705B2 (en) 2003-01-10 2015-06-23 Intranasal spray device containing pharmaceutical composition

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/047,388 Expired - Fee Related US8216604B2 (en) 2003-01-10 2008-03-13 Method of managing or treating pain
US13/541,325 Expired - Fee Related US9078814B2 (en) 2003-01-10 2012-07-03 Intranasal spray device containing pharmaceutical composition
US13/541,314 Expired - Fee Related US8889176B2 (en) 2003-01-10 2012-07-03 Method of managing or treating pain
US14/747,289 Expired - Fee Related US9814705B2 (en) 2003-01-10 2015-06-23 Intranasal spray device containing pharmaceutical composition

Country Status (25)

Country Link
US (5) US20040166067A1 (enExample)
EP (2) EP1635783B1 (enExample)
JP (1) JP4827725B2 (enExample)
KR (3) KR101012148B1 (enExample)
CN (1) CN100423709C (enExample)
AU (1) AU2004204381B2 (enExample)
BR (1) BRPI0406674B8 (enExample)
CA (1) CA2511974C (enExample)
CY (1) CY1115056T1 (enExample)
DK (1) DK1635783T5 (enExample)
EA (1) EA008500B1 (enExample)
ES (2) ES2432119T3 (enExample)
FR (1) FR14C0020I1 (enExample)
GB (1) GB0300531D0 (enExample)
GE (1) GEP20084340B (enExample)
IL (1) IL169480A (enExample)
MX (1) MXPA05007333A (enExample)
NO (1) NO335127B1 (enExample)
NZ (1) NZ541018A (enExample)
PL (1) PL212950B1 (enExample)
PT (2) PT1635783E (enExample)
SI (1) SI1635783T1 (enExample)
UA (1) UA85050C2 (enExample)
WO (1) WO2004062561A2 (enExample)
ZA (1) ZA200505274B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034059A1 (en) * 2000-07-31 2004-02-19 Jesper Grarup Fentanyl composition for nasal administration
US20110105551A1 (en) * 2002-03-19 2011-05-05 Vernalis (R&D) Limited Analgesics for nasal administration
US8889176B2 (en) 2003-01-10 2014-11-18 Depomed, Inc. Method of managing or treating pain
US12340996B2 (en) 2020-03-16 2025-06-24 Chinese Academy Of Inspection And Quarantine Method for rapid on-site detection of fentanyl analogs using a miniature mass spectrometer

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
KR20140017547A (ko) 2011-02-04 2014-02-11 아르키메데스 디벨로프먼트 리미티드 개량된 용기
SG194927A1 (en) 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
ES2748632T3 (es) 2012-10-03 2020-03-17 Proponent Biotech Gmbh Composición farmacéutica que comprende ácido propiónico para uso en el tratamiento de infecciones víricas
KR102321172B1 (ko) 2013-09-05 2021-11-05 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
MX2017010919A (es) 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
ES2968153T3 (es) * 2017-01-11 2024-05-08 Torrent Pharmaceuticals Ltd Composición nasal de tapentadol
US11207309B2 (en) 2019-07-19 2021-12-28 Hikma Pharmaceuticals International Limited Ready-to-administer fentanyl formulations
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
EP4146174A1 (en) 2020-05-06 2023-03-15 AB2 Bio SA Il-18 binding protein (il-18bp) in respiratory diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
EP4486367A1 (en) 2022-03-04 2025-01-08 AB2 Bio SA Il-18 binding protein (il-18bp) in the treatment of vexas

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164600A (en) * 1961-10-10 1965-01-05 Res Lab Dr C Janssen N V 1-aralkyl-4-(n-aryl-carbonyl amino)-piperidines and related compounds
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5655517A (en) * 1994-03-29 1997-08-12 Electrosols, Ltd. Dispensing device
US5735263A (en) * 1993-01-29 1998-04-07 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5910301A (en) * 1994-05-13 1999-06-08 Aradigm Corporation Method of intrapulmonary administration of a narcotic drug
US6387917B1 (en) * 1999-10-20 2002-05-14 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Salts of opioid analgesics, particularly morphine, and methods of using same
US6432440B1 (en) * 1997-04-18 2002-08-13 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6663883B1 (en) * 1999-08-26 2003-12-16 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2125212A (en) 1938-05-03 1938-07-26 Vick Chemical Company Therapeutic composition
US2730483A (en) 1952-08-12 1956-01-10 Nepera Chemical Co Inc Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine
US3184600A (en) 1963-05-07 1965-05-18 Potter Instrument Co Inc Photosensitive apparatus for measuring coordinate distances
JPS5885813A (ja) 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
HU193780B (en) 1985-06-21 1987-11-30 Richter Gedeon Vegyeszet Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62123112A (ja) 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
JPS62236862A (ja) 1986-04-09 1987-10-16 Nippon Kayaku Co Ltd 人工粘液
ZA875317B (en) 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
ES2042527T3 (es) 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
US4826683A (en) 1987-01-09 1989-05-02 Bates Harry L Decongestant
US5200180A (en) 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
DE3726797A1 (de) 1987-08-12 1989-02-23 Bayer Ag Arzneimittel fuer den bereich der mundhoehle
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE3827561C1 (enExample) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
JP2911496B2 (ja) 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5397771A (en) 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
EP0491076A1 (en) 1990-12-19 1992-06-24 Theratech, Inc. Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
EP0571671B1 (en) 1992-05-26 1997-09-17 The Procter & Gamble Company A Pharmaceutical composition in powder form
WO1994002119A1 (fr) 1992-07-23 1994-02-03 Hisamitsu Pharmaceutical Co., Inc. Composition de base administrable par injection percutanee et composition de medicament derivee
WO1994010987A1 (en) 1992-11-09 1994-05-26 Pharmetrix Corporation Combined analgesic delivery methods for pain management
DK0689438T3 (da) 1993-03-26 2003-09-29 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af apomorfin
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
SE9301877D0 (sv) 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
CA2167081A1 (en) 1993-07-12 1995-01-26 Alexander K. Andrianov Hydrogel microencapsulated vaccines
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
WO1995026715A2 (en) 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
JP3483148B2 (ja) 1994-04-21 2004-01-06 久光製薬株式会社 経皮投与基剤組成物およびその薬剤組成物
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
FR2733420B1 (fr) 1995-04-28 1997-06-27 Sep Tarral Preparations pectiques utilisables comme support de medicament
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
PT836511E (pt) 1995-06-05 2004-08-31 Alza Corp Dispositivo para distribuicao de fentanilo e sufentanilo por electrotransporte percutaneo
ZA964320B (en) 1995-06-05 1997-01-13 Alza Corp Device for transdermal electrotransport delivery of fentanyl and sufentanil
JP3098401B2 (ja) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
DE19527411A1 (de) * 1995-07-27 1997-01-30 Ackermann & Schmitt Gmbh & Co Kupplung
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
EP1024833A1 (en) 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6667279B1 (en) 1996-11-13 2003-12-23 Wallace, Inc. Method and composition for forming water impermeable barrier
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
CA2312839C (en) 1997-12-02 2008-01-15 Lisbeth Illum Compositions for nasal administration
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
CA2341732C (en) 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
JP2000229859A (ja) 1999-02-12 2000-08-22 Teijin Ltd 安定なブプレノルフィン経鼻製剤
JP2001002589A (ja) 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
JP2001089359A (ja) 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
JP4969009B2 (ja) 2000-03-10 2012-07-04 ダレクト コーポレーション オピオイド製剤
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
EP1296649A2 (en) 2000-06-22 2003-04-02 Pharmasol Limited Pharmaceutical compositions comprising an opioid analgesic
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
PT1307194E (pt) * 2000-07-31 2008-05-27 Nycomed Danmark Aps Composição à base de fentanil para administração nasal
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
GB2378383A (en) 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164600A (en) * 1961-10-10 1965-01-05 Res Lab Dr C Janssen N V 1-aralkyl-4-(n-aryl-carbonyl amino)-piperidines and related compounds
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5735263A (en) * 1993-01-29 1998-04-07 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5655517A (en) * 1994-03-29 1997-08-12 Electrosols, Ltd. Dispensing device
US5910301A (en) * 1994-05-13 1999-06-08 Aradigm Corporation Method of intrapulmonary administration of a narcotic drug
US6432440B1 (en) * 1997-04-18 2002-08-13 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces
US20070110677A1 (en) * 1997-04-18 2007-05-17 Archimedes Development Limited Delivery of drugs to mucosal surfaces
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6663883B1 (en) * 1999-08-26 2003-12-16 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
US6387917B1 (en) * 1999-10-20 2002-05-14 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Salts of opioid analgesics, particularly morphine, and methods of using same

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034059A1 (en) * 2000-07-31 2004-02-19 Jesper Grarup Fentanyl composition for nasal administration
US20070134164A1 (en) * 2000-07-31 2007-06-14 Jesper Grarup Fentanyl composition for nasal administration
US8017627B2 (en) 2000-07-31 2011-09-13 Nycomed Danmark Aps Fentanyl composition for nasal administration
US8158651B2 (en) 2000-07-31 2012-04-17 Nycomed Danmark Aps Fentanyl composition for nasal administration
US8653107B2 (en) 2000-07-31 2014-02-18 Takeda Pharma A/S Fentanyl composition for nasal administration
US20110105551A1 (en) * 2002-03-19 2011-05-05 Vernalis (R&D) Limited Analgesics for nasal administration
US8889176B2 (en) 2003-01-10 2014-11-18 Depomed, Inc. Method of managing or treating pain
US9078814B2 (en) 2003-01-10 2015-07-14 Depomed, Inc. Intranasal spray device containing pharmaceutical composition
US9814705B2 (en) 2003-01-10 2017-11-14 Depomed, Inc. Intranasal spray device containing pharmaceutical composition
US12340996B2 (en) 2020-03-16 2025-06-24 Chinese Academy Of Inspection And Quarantine Method for rapid on-site detection of fentanyl analogs using a miniature mass spectrometer

Also Published As

Publication number Publication date
ES2721899T3 (es) 2019-08-06
US20120277267A1 (en) 2012-11-01
BRPI0406674B1 (pt) 2015-12-22
JP2006516272A (ja) 2006-06-29
EA200501105A1 (ru) 2005-12-29
AU2004204381B2 (en) 2010-11-25
NZ541018A (en) 2008-07-31
CA2511974A1 (en) 2004-07-29
KR20100118144A (ko) 2010-11-04
BRPI0406674B8 (pt) 2021-05-25
CN100423709C (zh) 2008-10-08
US8889176B2 (en) 2014-11-18
EP2436375A1 (en) 2012-04-04
US8216604B2 (en) 2012-07-10
KR20090058596A (ko) 2009-06-09
BRPI0406674A (pt) 2005-12-20
US9078814B2 (en) 2015-07-14
UA85050C2 (ru) 2008-12-25
HK1088555A1 (en) 2006-11-10
ES2432119T3 (es) 2013-11-29
KR20050103275A (ko) 2005-10-28
WO2004062561A3 (en) 2004-10-07
PL212950B1 (pl) 2012-12-31
EP1635783B1 (en) 2013-09-18
MXPA05007333A (es) 2006-02-17
GB0300531D0 (en) 2003-02-12
CA2511974C (en) 2011-03-01
CN1723012A (zh) 2006-01-18
ZA200505274B (en) 2014-09-25
DK1635783T5 (da) 2014-05-12
CY1115056T1 (el) 2016-12-14
WO2004062561A2 (en) 2004-07-29
GEP20084340B (en) 2008-03-25
EP2436375B1 (en) 2019-02-27
NO20053119D0 (no) 2005-06-24
SI1635783T1 (sl) 2013-11-29
JP4827725B2 (ja) 2011-11-30
IL169480A (en) 2013-10-31
NO335127B1 (no) 2014-09-22
EA008500B1 (ru) 2007-06-29
DK1635783T3 (da) 2013-10-14
AU2004204381A2 (en) 2004-07-29
AU2004204381A1 (en) 2004-07-29
KR101012148B1 (ko) 2011-02-07
NO20053119L (no) 2005-08-03
PT1635783E (pt) 2013-10-29
PL377823A1 (pl) 2006-02-20
US9814705B2 (en) 2017-11-14
IL169480A0 (en) 2007-07-04
FR14C0020I1 (fr) 2014-04-18
PT2436375T (pt) 2019-05-24
US20080153879A1 (en) 2008-06-26
EP1635783A2 (en) 2006-03-22
US20120270903A1 (en) 2012-10-25
US20150283123A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
US9814705B2 (en) Intranasal spray device containing pharmaceutical composition
US20080221144A1 (en) Controlled Release Formulations
US7947257B2 (en) Method of intranasal administration of granisetron
HK1168539A (en) Pharmaceutical compositions comprising fentanyl for intranasal delivery
HK1088555B (en) Pharmaceutical compositions comprising fentanyl for intranasal delivery

Legal Events

Date Code Title Description
AS Assignment

Owner name: WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WATTS, PETER JAMES;CASTILE, JONATHAN DAVID;LAFFERTY, WILLIAM COLUMBUS IAN;AND OTHERS;REEL/FRAME:015319/0911;SIGNING DATES FROM 20040215 TO 20040217

AS Assignment

Owner name: ARCHIMEDES DEVELOPMENT LIMITED, UNITED KINGDOM

Free format text: CHANGE OF NAME;ASSIGNOR:WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED;REEL/FRAME:018798/0712

Effective date: 20050304

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: DEERFIELD PRIVATE DESIGN FUND III, L.P., NEW YORK

Free format text: SECURITY INTEREST;ASSIGNOR:DEPOMED, INC.;REEL/FRAME:035355/0039

Effective date: 20150402

AS Assignment

Owner name: ASSERTIO THERAPEUTICS, INC., ILLINOIS

Free format text: MERGER;ASSIGNOR:DEPOMED, INC.;REEL/FRAME:047322/0843

Effective date: 20180810

AS Assignment

Owner name: ASSERTIO THERAPEUTICS, INC., ILLINOIS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBERS 09402976, 10196590, 11562002,11562173,12047388,13078575,13541314,13541325, 14747289 PREVIOUSLY RECORDED ON REEL 047322 FRAME 0843. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNOR:DEPOMED, INC.;REEL/FRAME:049110/0550

Effective date: 20180810

AS Assignment

Owner name: ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.), ILLINOIS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEERFIELD PRIVATE DESIGN FUND III, L.P., AS COLLATERAL AGENT;REEL/FRAME:051930/0778

Effective date: 20200213